Uncategorized

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Published

on

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version